AL-'AQAR HEALTHCARE REIT |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.29 MYR | +0.78% |
|
+1.57% | +4.03% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Specialized REITs
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.03% | 230M | - | ||
| +2.23% | 679M | C+ | ||
| -6.87% | 608M | - | - | |
| -14.78% | 574M | - | - | |
| -3.06% | 410M | - | - | |
| -12.39% | 394M | - | - | |
| -22.69% | 312M | - | - | |
| -13.92% | 286M | - | - | |
| +0.49% | 232M | - | - | |
| -24.00% | 180M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- ALAQAR Stock
- Ratings Al-'Aqar Healthcare REIT
